The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable buzz within the industry. A shift away from Schedule I status, often regarded as outdated and hindering progress, could unlock significant opportunities for companies. Reduced regulatory burdens, alongside greater access to banking and investme